Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | DNA and RNA assay for myeloid malignancies

Michael Rauh, PhD, MD, FRCPC, Queen’s University School of Medicine, Kingston, Canada, provides an overview of the oncomine myeloid targeted-amplicon DNA and RNA ion semiconductor sequencing assay, highlighting its role in the management of myeloid malignancies. Dr Rauh explains that this assay is able to simultaneously detect DNA and RNA aberrations, providing information that is of diagnostic, prognostic, and therapeutic relevance, and thus complementing traditional cytogenetic techniques. This assay is also helpful to identify patients with clonal cytopenias of undetermined significance (CCUS) who could potentially develop myelodysplastic syndromes (MDS). This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

Disclosures

Michael Rauh, PhD, MD, FRCPC, has periodically provided informal feedback to Thermo Fisher over the last 3 years on Oncomine Myeloid NGS panel performance, receiving no remuneration; and has presented a talk at Thermo Fisher “Oncomine Day” in Toronto (October 24, 2019) where rail travel and overnight accommodations were provided.